Staff Profiles

Amanda C. Mitchell, Ph.D.

Scientist II

Amanda joined the Allen Institute in 2020. Her work focuses on novel single cell methodology and utilizing single cell epigenomics to create cell type specific tools to target every cell type in the brain. She received her B.S. in Molecular and Cellular Biology and her Ph.D. in Neuroscience from Vanderbilt University in Nashville, Tennessee. Her graduate dissertation in Karoly Mirnics’s lab explored physical activity transcriptome changes associated with neuroprotection in a MPTP model of Parkinson’s disease. Dr. Mitchell completed a postdoctoral fellowship in Schahram Akbarian’s lab at the Icahn School of Medicine at Mount Sinai, where she studied the role histone modifications and higher dimensional chromatin organization in neuropsychiatric diseases and modeled alterations in mice. Prior to joining the Allen Institute, she worked in genetic target identification at Merck for early discovery Neuroscience in the Department of Genetics and Pharmacogenomics. She brings a diverse skillset to the team.


Research Interests

Amanda uses functional genomics, genetics, and epigenetics datasets to identify noncoding regions, genes, cell types, and mechanisms critical for normal brain function & disease and to create novel molecular genetic tools.


  • Epigenomics
  • Functional genomics
  • Genetics
  • Molecular genetic tools

Research Programs

  • Molecular genetics
  • Cell types

Selected Publications View Publications

Disruption of an Evolutionarily Novel Synaptic Expression Pattern in Autism

PLoS Biology
September 26, 2019

Liu X, Han D, Somel M, Jiang X, Hu H, Guijarro P, Zhang N, Mitchell AC, Halene T, Ely JJ, Sherwood CC, Hof PR, Qiu Z, Pääbo S, Akbarian S, Khaitovich P

Cocaine-Induced Chromatin Modifications Associate With Increased Expression and Three-Dimensional Looping of Auts2

Biological Psychiatry
May 5, 2017

Olivia Engmann O, Labonté B, Mitchell A, Bashtrykov P, Calipari ES, Rosenbluh C, Loh YE, Walker DM, Burek D, Hamilton PJ, Issler O, Neve RL, Turecki G, Hurd Y, Chess A, Shen L, Mansuy I, Jeltsch A, Akbarian S, Nestler EJ

MEF2C transcription factor is associated with the genetic and epigenetic risk architecture of schizophrenia and improves cognition in mice

Molecular Psychiatry
January 24, 2017

Mitchell AC, Javidfar B, Pothula V, Ibi D, Shen EY, Peter CJ, Bicks LK, Fehr T, Jiang Y, Brennand KJ, Neve RL, Gonzalez-Maeso J, Akbarian S

Longitudinal assessment of neuronal 3D genomes in mouse prefrontal cortex

Nature Communications
September 6, 2016

Mitchell AC, Javidfar B, Bicks LK, Neve R, Garbett K, Lander SS, Mirnics K, Morishita H, Wood MA, Jiang Y, Gaisler-Salomon I, Akbarian S

Conserved Higher-Order Chromatin Regulates NMDA Receptor Gene Expression and Cognition

December 3, 2014

Vogel-Ciernia A, Shen EY, Mitchell AC, Mao W, Whittle C, Dincer A, Jakovcevski M, Pothula V, Rasmussen TP, Giakoumaki SG, Bitsios P, Sherif A, Gardner PD, Ernst P, Akbarian S

A Role for Noncoding Variation in Schizophrenia

Cell Press
November 20, 2014

Roussos P, Mitchell AC, Voloudakis G, Fullard JF, Pothula VM, Tsang J, Stahl EA, Georgakopoulos A, Ruderfer DM, Charney A, Okada Y, Siminovitch KA, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Plenge RM, Raychaudhuri S, Sklar P